nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—bone cancer	0.72	1	CbGaD
Bismuth Subsalicylate—PTGS2—Cisplatin—bone cancer	0.0784	0.709	CbGbCtD
Bismuth Subsalicylate—ALB—Methotrexate—bone cancer	0.0321	0.29	CbGbCtD
Bismuth Subsalicylate—Venous thrombosis—Carboplatin—bone cancer	0.00992	0.0874	CcSEcCtD
Bismuth Subsalicylate—TF—vertebral column—bone cancer	0.00907	0.32	CbGeAlD
Bismuth Subsalicylate—Fluid overload—Carboplatin—bone cancer	0.00861	0.0759	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Carboplatin—bone cancer	0.00614	0.0541	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00582	0.211	CbGpPWpGaD
Bismuth Subsalicylate—Haemolysis—Cisplatin—bone cancer	0.00494	0.0435	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Carboplatin—bone cancer	0.00451	0.0398	CcSEcCtD
Bismuth Subsalicylate—PTGS2—periosteum—bone cancer	0.0031	0.11	CbGeAlD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—FEV—bone cancer	0.00293	0.106	CbGpPWpGaD
Bismuth Subsalicylate—Venous thrombosis—Cisplatin—bone cancer	0.00291	0.0256	CcSEcCtD
Bismuth Subsalicylate—Fluid overload—Cisplatin—bone cancer	0.00253	0.0223	CcSEcCtD
Bismuth Subsalicylate—PTGS2—leg—bone cancer	0.00247	0.0873	CbGeAlD
Bismuth Subsalicylate—PTGS2—hindlimb—bone cancer	0.00221	0.078	CbGeAlD
Bismuth Subsalicylate—PTGS2—cartilage tissue—bone cancer	0.00217	0.0768	CbGeAlD
Bismuth Subsalicylate—TF—connective tissue—bone cancer	0.00191	0.0674	CbGeAlD
Bismuth Subsalicylate—Infection—Carboplatin—bone cancer	0.0019	0.0167	CcSEcCtD
Bismuth Subsalicylate—PTGS2—appendage—bone cancer	0.00189	0.0669	CbGeAlD
Bismuth Subsalicylate—Extravasation—Cisplatin—bone cancer	0.0018	0.0159	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Cisplatin—bone cancer	0.00165	0.0145	CcSEcCtD
Bismuth Subsalicylate—Pain—Carboplatin—bone cancer	0.00163	0.0144	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Carboplatin—bone cancer	0.00151	0.0133	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Cisplatin—bone cancer	0.0015	0.0132	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—bone cancer	0.00149	0.0132	CcSEcCtD
Bismuth Subsalicylate—TF—Differentiation Pathway—IL3—bone cancer	0.00149	0.0538	CbGpPWpGaD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—bone cancer	0.00139	0.0122	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—bone cancer	0.00138	0.0122	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Cisplatin—bone cancer	0.00132	0.0117	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—bone cancer	0.00128	0.0113	CcSEcCtD
Bismuth Subsalicylate—Deafness—Cisplatin—bone cancer	0.00128	0.0112	CcSEcCtD
Bismuth Subsalicylate—TF—bone marrow—bone cancer	0.00127	0.0449	CbGeAlD
Bismuth Subsalicylate—TF—spinal cord—bone cancer	0.00126	0.0447	CbGeAlD
Bismuth Subsalicylate—Burning sensation—Methotrexate—bone cancer	0.00124	0.0109	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Methotrexate—bone cancer	0.00122	0.0107	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet degranulation—SPARC—bone cancer	0.00119	0.0432	CbGpPWpGaD
Bismuth Subsalicylate—Burning sensation—Epirubicin—bone cancer	0.00116	0.0102	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Cisplatin—bone cancer	0.00115	0.0101	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—bone cancer	0.00114	0.01	CcSEcCtD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.00113	0.0411	CbGpPWpGaD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—bone cancer	0.00107	0.00947	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—bone cancer	0.00105	0.00929	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—bone cancer	0.000996	0.00877	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Methotrexate—bone cancer	0.000988	0.0087	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Cisplatin—bone cancer	0.000945	0.00832	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—bone cancer	0.000925	0.00815	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—bone cancer	0.000922	0.00812	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—FOLR1—bone cancer	0.000902	0.0327	CbGpPWpGaD
Bismuth Subsalicylate—TF—Differentiation Pathway—KIT—bone cancer	0.000867	0.0314	CbGpPWpGaD
Bismuth Subsalicylate—Extravasation—Doxorubicin—bone cancer	0.000856	0.00754	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Methotrexate—bone cancer	0.000823	0.00725	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Methotrexate—bone cancer	0.00078	0.00687	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—bone cancer	0.00077	0.00679	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—bone cancer	0.000737	0.00649	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Cisplatin—bone cancer	0.000736	0.00648	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—bone cancer	0.00073	0.00643	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—bone cancer	0.000713	0.00628	CcSEcCtD
Bismuth Subsalicylate—Erythema—Cisplatin—bone cancer	0.000687	0.00605	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—bone cancer	0.000682	0.00601	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Epirubicin—bone cancer	0.00068	0.00599	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—bone cancer	0.000675	0.00595	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Methotrexate—bone cancer	0.000639	0.00563	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—bone cancer	0.000629	0.00554	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—bone cancer	0.000598	0.00526	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—bone cancer	0.000588	0.00518	CcSEcCtD
Bismuth Subsalicylate—PTGS1—connective tissue—bone cancer	0.000566	0.02	CbGeAlD
Bismuth Subsalicylate—Oedema—Cisplatin—bone cancer	0.000561	0.00494	CcSEcCtD
Bismuth Subsalicylate—Infection—Cisplatin—bone cancer	0.000557	0.00491	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Doxorubicin—bone cancer	0.000553	0.00487	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—bone cancer	0.000544	0.00479	CcSEcCtD
Bismuth Subsalicylate—Asthma—Methotrexate—bone cancer	0.000541	0.00476	CcSEcCtD
Bismuth Subsalicylate—PTGS2—connective tissue—bone cancer	0.000541	0.0191	CbGeAlD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—bone cancer	0.000535	0.00471	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Cisplatin—bone cancer	0.000534	0.00471	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000528	0.0191	CbGpPWpGaD
Bismuth Subsalicylate—Abdominal discomfort—Methotrexate—bone cancer	0.000519	0.00457	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—bone cancer	0.000506	0.00446	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000501	0.0181	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.0005	0.0181	CbGpPWpGaD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—bone cancer	0.000495	0.00436	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Cisplatin—bone cancer	0.000487	0.00429	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000483	0.0175	CbGpPWpGaD
Bismuth Subsalicylate—Drowsiness—Methotrexate—bone cancer	0.000482	0.00425	CcSEcCtD
Bismuth Subsalicylate—Pain—Cisplatin—bone cancer	0.000479	0.00422	CcSEcCtD
Bismuth Subsalicylate—Asthma—Doxorubicin—bone cancer	0.000468	0.00413	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Cisplatin—bone cancer	0.000462	0.00407	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—bone cancer	0.000461	0.00406	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—JUN—bone cancer	0.00046	0.0167	CbGpPWpGaD
Bismuth Subsalicylate—Epistaxis—Methotrexate—bone cancer	0.000455	0.00401	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—bone cancer	0.000451	0.00398	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Cisplatin—bone cancer	0.000443	0.0039	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000442	0.016	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000438	0.0159	CbGpPWpGaD
Bismuth Subsalicylate—Hepatitis—Methotrexate—bone cancer	0.000433	0.00381	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—bone cancer	0.000426	0.00375	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—bone cancer	0.000426	0.00375	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—bone cancer	0.000418	0.00368	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00041	0.0149	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Methotrexate—bone cancer	0.000409	0.00361	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—bone cancer	0.000405	0.00357	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Methotrexate—bone cancer	0.000404	0.00356	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—bone cancer	0.000394	0.00347	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000392	0.0142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—tendon—bone cancer	0.000389	0.0137	CbGeAlD
Bismuth Subsalicylate—Diarrhoea—Cisplatin—bone cancer	0.000384	0.00338	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—bone cancer	0.000383	0.00337	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—bone cancer	0.000378	0.00333	CcSEcCtD
Bismuth Subsalicylate—Erythema—Methotrexate—bone cancer	0.000377	0.00332	CcSEcCtD
Bismuth Subsalicylate—PTGS1—spinal cord—bone cancer	0.000375	0.0132	CbGeAlD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—bone cancer	0.000375	0.0033	CcSEcCtD
Bismuth Subsalicylate—PTGS2—tendon—bone cancer	0.000372	0.0131	CbGeAlD
Bismuth Subsalicylate—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.00037	0.0134	CbGpPWpGaD
Bismuth Subsalicylate—Dysgeusia—Methotrexate—bone cancer	0.000369	0.00325	CcSEcCtD
Bismuth Subsalicylate—PTGS2—bone marrow—bone cancer	0.00036	0.0127	CbGeAlD
Bismuth Subsalicylate—PTGS2—spinal cord—bone cancer	0.000358	0.0127	CbGeAlD
Bismuth Subsalicylate—Vomiting—Cisplatin—bone cancer	0.000356	0.00314	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—bone cancer	0.000354	0.00312	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000354	0.0128	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Cisplatin—bone cancer	0.000353	0.00311	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Cisplatin—bone cancer	0.000353	0.00311	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—bone cancer	0.000353	0.00311	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—bone cancer	0.00035	0.00308	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—bone cancer	0.000345	0.00304	CcSEcCtD
Bismuth Subsalicylate—Nausea—Cisplatin—bone cancer	0.000333	0.00293	CcSEcCtD
Bismuth Subsalicylate—Erythema—Doxorubicin—bone cancer	0.000326	0.00287	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000325	0.0118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000324	0.0117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000322	0.0117	CbGpPWpGaD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—bone cancer	0.00032	0.00282	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Methotrexate—bone cancer	0.00031	0.00273	CcSEcCtD
Bismuth Subsalicylate—Infection—Methotrexate—bone cancer	0.000306	0.00269	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Methotrexate—bone cancer	0.000293	0.00258	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Epirubicin—bone cancer	0.00029	0.00256	CcSEcCtD
Bismuth Subsalicylate—Oedema—Epirubicin—bone cancer	0.000288	0.00254	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—bone cancer	0.000286	0.00252	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000286	0.0104	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Epirubicin—bone cancer	0.000274	0.00242	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Methotrexate—bone cancer	0.000273	0.00241	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—SPARC—bone cancer	0.000272	0.00987	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000272	0.00986	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Methotrexate—bone cancer	0.000271	0.00239	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Doxorubicin—bone cancer	0.000269	0.00237	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Methotrexate—bone cancer	0.000267	0.00236	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—bone cancer	0.000266	0.00235	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—bone cancer	0.000265	0.00233	CcSEcCtD
Bismuth Subsalicylate—Pain—Methotrexate—bone cancer	0.000263	0.00232	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Epirubicin—bone cancer	0.000256	0.00225	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—bone cancer	0.000254	0.00224	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Methotrexate—bone cancer	0.000253	0.00223	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—bone cancer	0.000253	0.00223	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—bone cancer	0.00025	0.0022	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—GNA11—bone cancer	0.000249	0.00902	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—DHFR—bone cancer	0.000248	0.00897	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Epirubicin—bone cancer	0.000246	0.00217	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—bone cancer	0.000246	0.00217	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000245	0.00889	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Methotrexate—bone cancer	0.000244	0.00215	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Methotrexate—bone cancer	0.000243	0.00214	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—bone cancer	0.000237	0.00209	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—bone cancer	0.000237	0.00209	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—bone cancer	0.000234	0.00207	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—bone cancer	0.000232	0.00204	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—JUN—bone cancer	0.000231	0.00838	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Epirubicin—bone cancer	0.000229	0.00201	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—bone cancer	0.000228	0.00201	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—bone cancer	0.000228	0.00201	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—bone cancer	0.000228	0.002	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—IL3—bone cancer	0.000226	0.00818	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—bone cancer	0.00022	0.00193	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Methotrexate—bone cancer	0.000218	0.00192	CcSEcCtD
Bismuth Subsalicylate—ALB—Platelet degranulation—SPARC—bone cancer	0.000217	0.00786	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Doxorubicin—bone cancer	0.000212	0.00186	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—bone cancer	0.000211	0.00185	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Methotrexate—bone cancer	0.00021	0.00185	CcSEcCtD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000207	0.00749	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Epirubicin—bone cancer	0.000204	0.00179	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Methotrexate—bone cancer	0.000203	0.00179	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000201	0.00728	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.0002	0.00725	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—bone cancer	0.000197	0.00173	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Methotrexate—bone cancer	0.000196	0.00172	CcSEcCtD
Bismuth Subsalicylate—Rash—Methotrexate—bone cancer	0.000194	0.00171	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methotrexate—bone cancer	0.000194	0.00171	CcSEcCtD
Bismuth Subsalicylate—Headache—Methotrexate—bone cancer	0.000193	0.0017	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Epirubicin—bone cancer	0.00019	0.00168	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Doxorubicin—bone cancer	0.000188	0.00166	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000187	0.00676	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Epirubicin—bone cancer	0.000183	0.00161	CcSEcCtD
Bismuth Subsalicylate—Nausea—Methotrexate—bone cancer	0.000183	0.00161	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—bone cancer	0.000182	0.00161	CcSEcCtD
Bismuth Subsalicylate—Rash—Epirubicin—bone cancer	0.000182	0.0016	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—bone cancer	0.000181	0.0016	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000181	0.00655	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Epirubicin—bone cancer	0.00018	0.00159	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Doxorubicin—bone cancer	0.000176	0.00155	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000172	0.00624	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Epirubicin—bone cancer	0.000171	0.00151	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Doxorubicin—bone cancer	0.000169	0.00149	CcSEcCtD
Bismuth Subsalicylate—Rash—Doxorubicin—bone cancer	0.000168	0.00148	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—bone cancer	0.000168	0.00148	CcSEcCtD
Bismuth Subsalicylate—Headache—Doxorubicin—bone cancer	0.000167	0.00147	CcSEcCtD
Bismuth Subsalicylate—Nausea—Doxorubicin—bone cancer	0.000158	0.00139	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000157	0.0057	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000152	0.0055	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PLAU—bone cancer	0.000148	0.00537	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000134	0.00484	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—GSTP1—bone cancer	0.00013	0.00471	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000129	0.00469	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.000125	0.00452	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000122	0.00441	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000115	0.00417	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000114	0.00412	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000111	0.00402	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000109	0.00396	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000109	0.00394	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CDK4—bone cancer	0.000101	0.00366	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	9.62e-05	0.00349	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.26e-05	0.00336	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NDUFA12—bone cancer	9.1e-05	0.0033	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	8.8e-05	0.00319	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—RB1—bone cancer	8.78e-05	0.00318	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	7.98e-05	0.00289	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NT5C3A—bone cancer	7.54e-05	0.00273	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.47e-05	0.00271	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	7.38e-05	0.00268	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NDUFA12—bone cancer	7.22e-05	0.00262	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.87e-05	0.00249	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.45e-05	0.00234	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MMP9—bone cancer	6.33e-05	0.00229	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NT5C3A—bone cancer	5.99e-05	0.00217	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—bone cancer	5.95e-05	0.00216	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NDUFA12—bone cancer	5.84e-05	0.00212	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—bone cancer	5.53e-05	0.00201	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—EGFR—bone cancer	5.12e-05	0.00185	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.09e-05	0.00185	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SPARC—bone cancer	4.96e-05	0.0018	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NT5C3A—bone cancer	4.84e-05	0.00176	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—GNA11—bone cancer	4.54e-05	0.00164	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.43e-05	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—bone cancer	4.3e-05	0.00156	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL3—bone cancer	4.11e-05	0.00149	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.48e-05	0.00126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ENO2—bone cancer	3.3e-05	0.0012	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ENO2—bone cancer	3.13e-05	0.00113	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—DHFR—bone cancer	3.06e-05	0.00111	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.92e-05	0.00106	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—DHFR—bone cancer	2.9e-05	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GNA11—bone cancer	2.86e-05	0.00104	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PLAU—bone cancer	2.7e-05	0.000978	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ENO2—bone cancer	2.62e-05	0.00095	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP3A4—bone cancer	2.6e-05	0.000941	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.58e-05	0.000936	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—DHFR—bone cancer	2.43e-05	0.000882	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GNA11—bone cancer	2.27e-05	0.000824	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTP1—bone cancer	2.22e-05	0.000805	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ENO2—bone cancer	2.12e-05	0.000769	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TGFBR2—bone cancer	2.1e-05	0.000763	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP3A4—bone cancer	2.06e-05	0.000747	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—DHFR—bone cancer	1.97e-05	0.000713	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GNA11—bone cancer	1.84e-05	0.000667	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTP1—bone cancer	1.76e-05	0.000639	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP3A4—bone cancer	1.67e-05	0.000604	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.66e-05	0.000601	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KIT—bone cancer	1.44e-05	0.000521	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTP1—bone cancer	1.43e-05	0.000517	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BRAF—bone cancer	1.35e-05	0.000489	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—bone cancer	1.15e-05	0.000417	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MDM2—bone cancer	1.13e-05	0.00041	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—bone cancer	1.08e-05	0.000393	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—bone cancer	7.73e-06	0.00028	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—bone cancer	7.39e-06	0.000268	CbGpPWpGaD
